SpringWorks Therapeutics Stock (NASDAQ:SWTX)


ForecastRevenueFinancialsChartTranscripts

Previous Close

$37.93

52W Range

$20.19 - $53.92

50D Avg

$32.61

200D Avg

$40.12

Market Cap

$2.79B

Avg Vol (3M)

$1.05M

Beta

0.79

Div Yield

-

SWTX Company Profile


SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

305

IPO Date

Sep 13, 2019

Website

SWTX Performance


SWTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$5.45M$6.15M-
Operating Income$-343.01M$-280.67M$-173.47M
Net Income$-325.10M$-274.16M$-173.21M
EBITDA$-341.35M$-280.67M$-172.98M
Basic EPS$-0.01$-5.14$-3.57
Diluted EPS$-0.01$-5.14$-3.57

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 1:20 PM
Q2 24Aug 07, 24 | 1:08 PM
Q1 24May 05, 24 | 2:22 AM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
SANASana Biotechnology, Inc.
KYMRKymera Therapeutics, Inc.
ARVNArvinas, Inc.
RVMDRevolution Medicines, Inc. Warrant
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
CERECerevel Therapeutics Holdings, Inc.
RNAAvidity Biosciences, Inc.
BDTXBlack Diamond Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
BCELAtreca, Inc.
TERNTerns Pharmaceuticals, Inc.
PASGPassage Bio, Inc.
GLUEMonte Rosa Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.